Headquartered in New York, NY Fiscal year ends December NASDAQ: MGTX meiragtx.com
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies with local delivery of small doses for disease-modifying effects. The company has a broad pipeline with four late-stage clinical programs spanning inherited and common diseases in ophthalmology (XLRP with bota-vec, LCA4 with AAV-AIPL1), radiation-induced xerostomia (AAV2-hAQP1), and Parkinson's disease (AAV-GAD). MeiraGTx has built comprehensive end-to-end in-house manufacturing capabilities, including two GMP-licensed viral vector production facilities and a GMP QC facility with commercial licensure. The company has developed proprietary technology in capsid and promoter optimization, novel translational control elements, and a transformative riboswitch gene regulation platform that enables precise, dose-responsive control of gene expression using oral small molecules. The riboswitch platform is being applied to metabolic peptide delivery (including leptin, GLP-1, and others), cell therapy including CAR-T, and neuropathic pain. MeiraGTx maintains strategic collaborations with Eli Lilly (LCA4 and ophthalmology technologies), Reogen/Hologen (AAV-GAD for Parkinson's), and a financing arrangement with Oberland Capital. The company is transitioning toward commercialization with potential first product launches anticipated in 2027-2028. Updated
Penny stocks represent an interesting investment opportunity. These stocks typically represent small companies or companies that are early in the development stages. But isn’t that how you make it big in the…
MeiraGTx is a vertically integrated, clinical-stage genetic medicines company focused on developing gene therapies with local delivery of small doses for disease-modifying effects.
The Wall Street consensus 12-month price target for MGTX is $27.75.
